CORRECTION article

Front. Pharmacol., 09 November 2022

Sec. Pharmacoepidemiology

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1075966

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system

  • 1. Division of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China

  • 2. Clinical Experimental Center, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, China

  • 3. Department of Pathology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China

In the original article, there was an error in affiliation 1. Instead of “Division of Psychopharmacology, Department of Pharmacy, The Third People’s Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”, it should be “Division of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”. In the published article, there was an error in affiliation 3. Instead of “Department of Pathology, The Third People’s Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”, it should be “Department of Pathology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

esketamine, pharmacovigilance, neurological adverse events, signal, FAERS, disproportionality analysis

Citation

Guo H, Wang B, Yuan S, Wu S, Liu J, He M and Wang J (2022) Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system. Front. Pharmacol. 13:1075966. doi: 10.3389/fphar.2022.1075966

Received

21 October 2022

Accepted

24 October 2022

Published

09 November 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Jing Liu, ; Miaoquan He, ; Jisheng Wang,

This article was submitted to Pharmacoepidemiology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics